mRNA Flu/COVID-19 Vaccine for Healthy Adults

This trial tests a new mRNA vaccine designed to protect against both the flu and COVID-19. Researchers aim to assess the vaccine's safety and its effectiveness in helping the body build defenses against these viruses. Participants will receive either the new combined vaccine at varying doses or a standard flu or COVID-19 vaccine for comparison. The trial seeks healthy adults aged 65 to 85 who haven't recently received a flu or COVID-19 vaccine. Researchers will closely monitor for any side effects and evaluate the vaccine's effectiveness over time. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new vaccine.

The trial information does not specify if you need to stop taking your current medications. However, it does mention restrictions on recent vaccinations, so it's best to discuss your specific medications with the trial team.

An earlier study showed that the new mRNA vaccine for both the flu and COVID-19 had good safety results. Researchers found no major safety issues, and participants experienced no unexpected side effects. Common reactions were mild, such as soreness at the injection site and temporary fatigue.

Ongoing safety checks have identified no serious problems, indicating that the vaccine is well-tolerated by recipients. This vaccine uses mRNA technology, which has been safely used in COVID-19 vaccines.

Researchers are excited about the investigational mRNA Seasonal Flu/COVID-19 combination vaccine (Flu/COVm) because it combines protection against both the flu and COVID-19 in a single shot, which is not currently available with existing vaccines. Traditional vaccines typically target these viruses separately, requiring multiple doses for full protection. This mRNA-based approach could streamline immunization efforts by delivering a combined dose, potentially enhancing convenience and compliance. Additionally, mRNA technology is known for its rapid adaptability, which could be crucial in responding to new virus strains more quickly than conventional methods.

Research has shown that the new mRNA seasonal flu/COVID-19 combination vaccine, mRNA-1083, boosts the body's defenses effectively. In earlier studies, this vaccine generated stronger immune responses against flu strains like H1N1 compared to other vaccines. It matched the effectiveness of other vaccines in protecting against both flu and COVID-19. Another study demonstrated that this mRNA vaccine provided better protection against illness than standard flu vaccines in older adults. This trial will test different dose levels of the mRNA-1083 vaccine to evaluate its effectiveness and safety. These findings suggest that the combination vaccine could effectively protect against both seasonal flu and COVID-19.¹²³⁶⁷